DAC Beachcroft LLP & the Fast-Evolving Cannabis Space

 
dacb-logo-print.png

We are delighted to announce DAC Beachcroft LLP as the sponsor of our First Wednesdays Christmas Special. To learn more about the firm and their services, we asked 3 questions to Jonathan Deverill, Corporate Partner and Medical Cannabis Team Leader at DAC Beachcroft LLP.

First Wednesdays, October 2018

First Wednesdays, October 2018

Who are DAC Beachcroft LLP?

DAC Beachcroft LLP is a leading international legal business with offices across Europe, Asia Pacific and Latin America and close links to law firms in other parts of the world, including across Canada and the USA.

A “full service” leader, we are recognised leaders in Health, Insurance, and Real Estate and draw on the knowledge, industry experience and commercial expertise of our 2,400 lawyers and support colleagues in these sectors and beyond.

What services do you offer to the medical cannabis industry?

Our DAC Beachcroft Medical Cannabis team supports both domestic and overseas clients on a variety of matters in this fast-evolving, entrepreneurial sector. I lead the team, with expertise drawn from across our health, public law, corporate, life sciences and product liability teams. Examples of recent projects include M&A and joint ventures, advice on the retail sale of certain CBD wellness products, work relating to the 1 November 2018 change to UK law around medical cannabis and helping clients with certain UK-based medical cannabis cultivation projects.

Together with the firm's Public Law and Health teams, we are also able to guide clients through the process of having a cannabis-based medicine approved by the Medicines and Healthcare products Regulatory Agency for use in the UK.

In addition to advising clients, our team has built a network of contacts in the industry, including financiers, consultants and other professionals, all of whom understand the medical cannabis field and to whom clients can be introduced where this is beneficial. Our team works with its Corporate Finance colleagues to advise on fundraisings and listings in the UK and elsewhere, including on London's Main Market, AIM and the NEX Exchange.

How do you expect the industry to evolve?

From what we are seeing, the UK medical cannabis sector looks set to grow very quickly, driven by both fast-moving domestic businesses and more established overseas players. It is very international and I’m sure the experience to date in Canada and some other countries will be valuable as the industry expands here. It feels as if a lot has changed already since the start of 2018 and we anticipate seeing many more listings and new medical products in 2019 and beyond.

Learn more about DAC Beachcroft and their services here.

 
Pierre-Yves Gallety